Primary hyperoxaluria type 2
- Oxalosis 2
- Glyoxylate reductase/hydroxypyruvate reductase deficiency
- Glyceric aciduria
- D-glycerate dehydrogenase deficiency
News & Events
On this page
ORDR Co-Sponsored Conferences
2016 Rare Disease Day at NIH, Monday, February 29, 2016
Location: Building 10, Masur Auditorium, National Institutes of Health, Bethesda, MD
Description: The 2016 Rare Disease Day at NIH will take place on February 29. The event, sponsored by NCATS and the NIH Clinical Center, aims to raise awareness about rare diseases, the patients they affect and the research collaborations that are addressing rare disease challenges. The day will feature tours, posters and exhibits, and presentations.
Ninth International Primary Hyperoxaluria Workshop, Saturday, August 28, 2010 - Sunday, August 29, 2010
Location: New York, NY
Description: The goals of this workshop were to (1) bring together the multidisciplinary primary hyperoxaluria (PH) treatment and research communities for dialogue and interaction in order to better understand the etiology of the PHs, optimize diagnosis and treatment strategies, and identify novel research and treatment approaches; (2) foster new collaborations among U.S. and international researchers and clinicians from a variety of backgrounds; (3) encourage the entry of new and junior researchers into the field of research on PHs and other oxalate-related diseases; and (4) inform PH patients, families, and friends of the latest advances in the understanding and clinical management of PHs.
Research Challenges in CNS Manifestations of Inborn Errors of Metabolism Workshop, Monday, December 07, 2009 - Wednesday, December 09, 2009
Location: Bethesda North Marriott, Bethesda, Maryland
Description: Jointly sponsored by the National Institute of Health's Office Rare Diseases Research, the National Institute of Neurological Disorders and Stroke, and the Food and Drug Administration's Center for Drug Evaluation and Research, Division of Gastroenterology Products, the goal of this workshop is to bring together those involved in research and investigational treatments for central nervous system aspects of inborn errors of metabolism, and to discuss ways to translate these therapies to clinical trials and beyond.